Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs
Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.
You may also be interested in...
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.
The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.